EU/3/10/750

Table of contents

About

On 9 June 2010, orphan designation (EU/3/10/750) was granted by the European Commission to Sanofi-Aventis, France, for rifapentine for the treatment of tuberculosis.

In October 2012, Sanofi-Aventis changed name to Sanofi-Aventis Groupe.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Rifapentine
Disease / condition
Treatment of tuberculosis
Date of first decision
09/06/2010
Outcome
Positive
EU designation number
EU/3/10/750

Sponsor's contact details

Sanofi-Aventis Groupe
54 rue de la Boétie
75008 Paris
France
Tel. +33 153 774 000
Fax +33 153 774 133
www.sanofi-aventis.com/contact/contact.asp

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating